|
Toggle Summary
March 19, 2015
|
Minerva Neurosciences to Host Fourth Quarter and Full Year 2014 Financial Results Webcast and Conference Call
|
Minerva Neurosciences to Host Fourth Quarter and Full Year 2014 Financial Results Webcast and Conference Call
|
|
Toggle Summary
March 18, 2015
|
Minerva Neurosciences Completes Private Placement, Raises $31 Million
|
Minerva Neurosciences Completes Private Placement, Raises $31 Million
|
|
Toggle Summary
March 13, 2015
|
Minerva Neurosciences Announces $31 Million Financing
|
Minerva Neurosciences Announces $31 Million Financing
|
|
Toggle Summary
January 21, 2015
|
Minerva Neurosciences Reports Positive Phase 1 Data With MIN-202, Selective Orexin-2 Antagonist for Treatment of Sleep Disorders Including Primary and Comorbid Insomnia
|
Minerva Neurosciences Reports Positive Phase 1 Data With MIN-202, Selective Orexin-2 Antagonist for Treatment of Sleep Disorders Including Primary and Comorbid Insomnia
|
|
Toggle Summary
January 20, 2015
|
Minerva Neurosciences Announces $15 Million Debt Facility With Oxford Finance LLC and Silicon Valley Bank
Funding supports Minerva continuing to advance the clinical program for MIN-101, the company's investigational compound in development for treatment of schizophrenia
|
Minerva Neurosciences Announces $15 Million Debt Facility With Oxford Finance LLC and Silicon Valley Bank
|
|
Toggle Summary
January 5, 2015
|
Minerva Neurosciences Reports Positive Data Showing an Analog of Minerva's MIN-301 Compound Improves Symptoms of Parkinson's Disease in Primates
|
Minerva Neurosciences Reports Positive Data Showing an Analog of Minerva's MIN-301 Compound Improves Symptoms of Parkinson's Disease in Primates
|
|
Toggle Summary
December 3, 2014
|
Minerva Neurosciences Announces Completion of Development and Final Selection of Once-Daily Dose Formulation of MIN-101 for Its Schizophrenia Program
New Formulation to be Used in Planned Phase 2b Clinical Trial Has Been Developed to Offer Improved Safety, Tolerability and Pharmacokinetic Profile
|
Minerva Neurosciences Announces Completion of Development and Final Selection of Once-Daily Dose Formulation of MIN-101 for Its Schizophrenia Program
|
|
Toggle Summary
November 25, 2014
|
Minerva Neurosciences Appoints Dr. Remy Luthringer as CEO
|
Minerva Neurosciences Appoints Dr. Remy Luthringer as CEO
|
|
Toggle Summary
November 13, 2014
|
Dr. Remy Luthringer, Minerva President and Chief Scientific Officer, to Present at CNS Summit
|
Dr. Remy Luthringer, Minerva President and Chief Scientific Officer, to Present at CNS Summit
|
|
Toggle Summary
November 6, 2014
|
Minerva Neurosciences Reports Third Quarter 2014 Financial Results
|
Minerva Neurosciences Reports Third Quarter 2014 Financial Results
|
